Predicting Treatment of Bioprosthetic Aortic Valve Failure in the United States: A Proposed Model
Year: 2024
Type: editorial
Abstract: Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are two recognized therapies for aortic stenosis (AS). Similarly, the use of a transcatheter aortic valve inside a failed surgical or transcatheter aortic valve has become an established strategy to treat patients. These valve-in-valve (ViV) procedures can be challenging and carry some inherent procedural risks, especially with regard to coronary obstruction, future coronary access, and valve performance. Understanding the trends in TAVR and SAVR utilization is important to predict the use of ViV TAVR in the future, which are major determinants for the lifetime management of AS.
Source: Structural Heart
Institutions: Morristown Medical Center, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, Cardiovascular Research Foundation, Cleveland Clinic, Ariel University, Heart Hospital Baylor Plano, Institut universitaire de cardiologie et de pneumologie de Québec, Hebrew University of Jerusalem, Shaare Zedek Medical Center, Bikur Cholim Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4400514475